Crescita Therapeutics Inc.
CRRTF
$0.56
$0.00-0.85%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 64.48% | -13.37% | 48.59% | 50.79% | -33.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.48% | -13.37% | 48.59% | 50.79% | -33.49% |
| Cost of Revenue | 57.03% | -27.37% | 54.47% | 28.52% | -28.51% |
| Gross Profit | 73.81% | 13.29% | 43.73% | 69.26% | -38.83% |
| SG&A Expenses | 56.02% | 19.12% | -7.46% | -3.35% | -15.57% |
| Depreciation & Amortization | 14.36% | -40.51% | 21.85% | 14.81% | -57.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.53% | -11.27% | 15.42% | 8.88% | -24.56% |
| Operating Income | -17.09% | -42.72% | 86.31% | 155.23% | -36.48% |
| Income Before Tax | -28.44% | -300.56% | 171.97% | 185.24% | -39.87% |
| Income Tax Expenses | -- | 165.00% | -- | -- | -- |
| Earnings from Continuing Operations | -28.44% | -340.80% | 171.97% | 185.24% | -39.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.44% | -340.80% | 171.97% | 185.24% | -39.87% |
| EBIT | -17.09% | -42.72% | 86.31% | 155.23% | -36.48% |
| EBITDA | -19.07% | -253.88% | 125.57% | 225.09% | -92.52% |
| EPS Basic | -31.38% | -349.18% | 173.60% | 187.64% | -43.88% |
| Normalized Basic EPS | -31.46% | 86.36% | 201.22% | 187.16% | -43.92% |
| EPS Diluted | -31.38% | -297.10% | 173.60% | 179.18% | -43.88% |
| Normalized Diluted EPS | -31.46% | 86.36% | 201.22% | 186.70% | -43.92% |
| Average Basic Shares Outstanding | -2.18% | -2.66% | -2.26% | -2.62% | -2.88% |
| Average Diluted Shares Outstanding | -2.18% | -2.66% | -2.20% | -2.09% | -2.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |